Review



natural terpenoid compound library  (Selleck Chemicals)


Bioz Verified Symbol Selleck Chemicals is a verified supplier
Bioz Manufacturer Symbol Selleck Chemicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Selleck Chemicals natural terpenoid compound library
    Primary screening of a <t>terpenoid</t> <t>compound</t> <t>library</t> against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.
    Natural Terpenoid Compound Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1335 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Compound/pmc13748739-35-1-11
    Average 96 stars, based on 1335 article reviews
    natural terpenoid compound library - by Bioz Stars, 2026-11
    96/100 stars

    Images

    1) Product Images from "Identification of valepotriate as a novel antimycobacterial agent against drug-resistant Mycobacterium tuberculosis through screening of a natural terpenoid compound library"

    Article Title: Identification of valepotriate as a novel antimycobacterial agent against drug-resistant Mycobacterium tuberculosis through screening of a natural terpenoid compound library

    Journal: JAC-Antimicrobial Resistance

    doi: 10.1093/jacamr/dlag250

    Primary screening of a terpenoid compound library against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.
    Figure Legend Snippet: Primary screening of a terpenoid compound library against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.

    Techniques Used: Screening, Drug discovery, Cell Culture, Concentration Assay, Inhibition, Bacteria, Negative Control, Positive Control

    Related Articles

    Imaging:

    Article Title: Mesoscale Soft Robotics for Mechanically Perturbing and Functionally Monitoring Responses in Human Organoids
    Article Snippet: .. From day 15 until transition to the imaging medium, organoids were treated with a four-compound small-molecule cocktail consisting of GSK2879552 2HCl (Selleckchem, S7796), EPZ-5676 (Selleckchem, S7062), Bay K 8644 (Selleckchem, S7924), and NMDA (Selleckchem, S7072), each at 1 μM, to enhance neuronal maturation, as previously described 41 . .. Prior to functional experiments, cortical organoids were transduced with an adeno-associated virus encoding the genetically encoded calcium indicator GCaMP6f (Addgene, 100837-AAV1).

    Organoids:

    Article Title: Mesoscale Soft Robotics for Mechanically Perturbing and Functionally Monitoring Responses in Human Organoids
    Article Snippet: .. From day 15 until transition to the imaging medium, organoids were treated with a four-compound small-molecule cocktail consisting of GSK2879552 2HCl (Selleckchem, S7796), EPZ-5676 (Selleckchem, S7062), Bay K 8644 (Selleckchem, S7924), and NMDA (Selleckchem, S7072), each at 1 μM, to enhance neuronal maturation, as previously described 41 . .. Prior to functional experiments, cortical organoids were transduced with an adeno-associated virus encoding the genetically encoded calcium indicator GCaMP6f (Addgene, 100837-AAV1).

    Inhibition:

    Article Title: Multi-omics analysis of LFA-1 peptide-functionalized silk fibroin nanofibers targeting RPE and activating AMPK–HO-1 signaling to suppress pyroptosis and alleviate diabetic retinopathy progression
    Article Snippet: Diabetic retinopathy (DR) is one of the leading causes of adult blindness, and pyroptosis of retinal pigment epithelial (RPE) cells plays a key role in its pathogenesis.. To achieve precise delivery of the multiple active components of the traditional Chinese medicine formula Zishen Jianpi Huayu Pills (ZSJP) to DR lesions, we constructed an LFA-1 peptide-modified silk fibroin nanofiber system (PCL/SF-L@ZSJP) that targets and activates the AMPK/HO-1 signaling pathway in RPE cells.. Nanofibers were prepared by coaxial electrospinning and systematically characterized.

    Drug discovery:




    Similar Products

    95
    TargetMol clinical stage compounds
    Clinical Stage Compounds, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Clinical+Compound+Library/10__1021_slash_acs__jmedchem__6c01726-423-7-11
    Average 95 stars, based on 1 article reviews
    clinical stage compounds - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    Selleck Chemicals natural terpenoid compound library
    Primary screening of a <t>terpenoid</t> <t>compound</t> <t>library</t> against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.
    Natural Terpenoid Compound Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Compound/pmc13748739-35-1-11
    Average 96 stars, based on 1 article reviews
    natural terpenoid compound library - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    90
    TargetMol anti cardiovascular disease compound library
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Anti Cardiovascular Disease Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Anti-Cardiovascular+Disease+Compound+Library/pmc13748904-58-22-21
    Average 90 stars, based on 1 article reviews
    anti cardiovascular disease compound library - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    96
    TargetMol pharmacopeia compound library
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Pharmacopeia Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/FDA-Approved+Drug+Library/10__1038_slash_s41419___026___09401___w-74-10-7
    Average 96 stars, based on 1 article reviews
    pharmacopeia compound library - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    95
    TargetMol compound library
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Clinical+Compound+Library/pm42966158-42-0-11
    Average 95 stars, based on 1 article reviews
    compound library - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    Selleck Chemicals organoid based drug screening
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Organoid Based Drug Screening, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Epigenetics+Compound+Library/pmc13683295-285-4-13
    Average 94 stars, based on 1 article reviews
    organoid based drug screening - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol drug screen
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Drug Screen, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Cell+Cycle+Compound+Library/pm42901431-305-15-20
    Average 94 stars, based on 1 article reviews
    drug screen - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol endoplasmic reticulum er stress
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Endoplasmic Reticulum Er Stress, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Endoplasmic+Reticulum+Stress+Compound+Library/pm42896314-137-3-21
    Average 94 stars, based on 1 article reviews
    endoplasmic reticulum er stress - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    96
    TargetMol ferroptosis
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Ferroptosis, supplied by TargetMol, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Ferroptosis+Compound+Library/pm42896314-137-8-21
    Average 96 stars, based on 1 article reviews
    ferroptosis - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    97
    TargetMol acta pharmacologica sinica (2026) 0
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Acta Pharmacologica Sinica (2026) 0, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Bioactive+Compound+Library/pm42875556-80-6-21
    Average 97 stars, based on 1 article reviews
    acta pharmacologica sinica (2026) 0 - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    Image Search Results


    Primary screening of a terpenoid compound library against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.

    Journal: JAC-Antimicrobial Resistance

    Article Title: Identification of valepotriate as a novel antimycobacterial agent against drug-resistant Mycobacterium tuberculosis through screening of a natural terpenoid compound library

    doi: 10.1093/jacamr/dlag250

    Figure Lengend Snippet: Primary screening of a terpenoid compound library against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.

    Article Snippet: A natural terpenoid compound library containing 354 compounds was purchased from Selleck Chemicals (L1420, Selleck Chemicals, USA).

    Techniques: Screening, Drug discovery, Cell Culture, Concentration Assay, Inhibition, Bacteria, Negative Control, Positive Control

    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Journal: Advanced Science

    Article Title: Targeting a Calcium‐Associated Mitochondrial Vulnerability in TET2‐Deficient Myeloid Cells

    doi: 10.1002/advs.78748

    Figure Lengend Snippet: Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Article Snippet: To identify compounds that preferentially compromise TET2 ‐KD macrophages, we performed chemical‐genetic screening using 489 cardiovascular disease‐related bioactive compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library (Figure and Extended Data Table ).

    Techniques: Screening, Derivative Assay, Drug discovery, Preserving, Biomarker Discovery, Alamar Blue Assay, Activity Assay, MTS Assay, Transfection, Enzyme-linked Immunosorbent Assay, RNA Sequencing